Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Piribedil is an antiparkinsonian agent and piperazine derivative which acts as a D2 and D3 receptor agonist. It also has α2-adrenergic antagonist properties.
Applications, Medical uses & Side effects
Explore the main themes, entities and connections around Piribedil. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
receptor citation needed effect antagonist d2 agonist d3 also medical side pathological elderly attention memory dizziness drug normal piperazine derivative
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Piribedil | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Piribedil | AHFS/Drugs.com | International Drug Names | 1.00 | infobox |
| Piribedil | ATC code | N04BC08 (WHO) | 1.00 | infobox |
| Piribedil | Bioavailability | 10% (peak at 1 hour) [citation needed] | 1.00 | infobox |
| Piribedil | CAS Number | 3605-01-4 Y | 1.00 | infobox |
| Piribedil | ChEMBL | ChEMBL1371770 N | 1.00 | infobox |
| Piribedil | ChemSpider | 4684 N | 1.00 | infobox |
| Piribedil | CompTox Dashboard (EPA) | DTXSID9045188 | 1.00 | infobox |
| Piribedil | ECHA InfoCard | 100.020.695 | 1.00 | infobox |
| Piribedil | Elimination half-life | 1.7–6.9 hours [citation needed] | 1.00 | infobox |
| Piribedil | Excretion | Kidney (68%) and bile duct (25%) [citation needed] | 1.00 | infobox |
| Piribedil | Formula | C16H18N4O2 | 1.00 | infobox |
| Piribedil | IUPHAR/BPS | 49 | 1.00 | infobox |
| Piribedil | KEGG | D07305 Y | 1.00 | infobox |
| Piribedil | Legal status | EU: Rx-only | 1.00 | infobox |
| Piribedil | Legal status | In general: ℞ (Prescription only) | 1.00 | infobox |
| Piribedil | Metabolism | extensive liver [citation needed] | 1.00 | infobox |
| Piribedil | Molar mass | 298.346 g·mol−1 | 1.00 | infobox |
| Piribedil | Protein binding | 70–80% [citation needed] | 1.00 | infobox |
| Piribedil | PubChem CID | 4850 | 1.00 | infobox |
| Piribedil | Routes of administration | By mouth | 1.00 | infobox |
| Piribedil | Trade names | Pronoran, Trivastal Retard, Trastal, Trivastan, Clarium, others | 1.00 | infobox |
| Piribedil | UNII | DO22K1PRDJ | 1.00 | infobox |
| Piribedil | is a | antiparkinsonian agent and piperazine derivative which acts as a D2 and D3 receptor agonist | 0.90 | text |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.